- Home
- IGMS vs NUS Comparison
IGMS vs NUS Comparison
Compare IGMS & NUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- NUS
- Stock Information
- Founded
- IGMS 1993
- NUS 1984
- Country
- IGMS United States
- NUS United States
- Employees
- IGMS N/A
- NUS 15200
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- NUS Other Pharmaceuticals
- Sector
- IGMS Health Care
- NUS Health Care
- Exchange
- IGMS Nasdaq
- NUS Nasdaq
- Market Cap
- IGMS 348.5M
- NUS 348.5M
- IPO Year
- IGMS 2019
- NUS 1996
- Fundamental
- Price
- IGMS $1.77
- NUS $7.00
- Analyst Decision
- IGMS Hold
- NUS Hold
- Analyst Count
- IGMS 8
- NUS 2
- Target Price
- IGMS $6.14
- NUS $6.88
- AVG Volume (30 Days)
- IGMS 779.9K
- NUS 922.8K
- Earning Date
- IGMS 03-06-2025
- NUS 02-13-2025
- Dividend Yield
- IGMS N/A
- NUS 3.42%
- EPS Growth
- IGMS N/A
- NUS N/A
- EPS
- IGMS N/A
- NUS N/A
- Revenue
- IGMS $2,918,000.00
- NUS $1,775,172,000.00
- Revenue This Year
- IGMS $23.57
- NUS N/A
- Revenue Next Year
- IGMS $192.36
- NUS N/A
- P/E Ratio
- IGMS N/A
- NUS N/A
- Revenue Growth
- IGMS 57.64
- NUS N/A
- 52 Week Low
- IGMS $1.59
- NUS $5.95
- 52 Week High
- IGMS $22.50
- NUS $19.30
- Technical
- Relative Strength Index (RSI)
- IGMS 19.54
- NUS 50.87
- Support Level
- IGMS $1.59
- NUS $6.77
- Resistance Level
- IGMS $2.06
- NUS $7.15
- Average True Range (ATR)
- IGMS 0.45
- NUS 0.43
- MACD
- IGMS -0.30
- NUS 0.03
- Stochastic Oscillator
- IGMS 3.27
- NUS 39.60
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About NUS Nu Skin Enterprises Inc.
Nu Skin Enterprises Inc is a health and beauty direct-selling company. It has two primary product categories: beauty products and wellness products. The company develops and distributes nutritional, weight-management products, and food supplements under the Nu Skin and Pharmanex brands, respectively. The company has operations internationally, in more than 50 countries across the Americas, Europe, and the Asia-Pacific.